CN102639009B - 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物 - Google Patents

用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物 Download PDF

Info

Publication number
CN102639009B
CN102639009B CN201080040828.XA CN201080040828A CN102639009B CN 102639009 B CN102639009 B CN 102639009B CN 201080040828 A CN201080040828 A CN 201080040828A CN 102639009 B CN102639009 B CN 102639009B
Authority
CN
China
Prior art keywords
vitamin
thyroid
individual
folic acid
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080040828.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102639009A (zh
Inventor
林齐·O·斯科特三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510784785.0A priority Critical patent/CN105476997B/zh
Publication of CN102639009A publication Critical patent/CN102639009A/zh
Application granted granted Critical
Publication of CN102639009B publication Critical patent/CN102639009B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080040828.XA 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物 Active CN102639009B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510784785.0A CN105476997B (zh) 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27061509P 2009-07-10 2009-07-10
US61/270615 2009-07-10
US27074109P 2009-07-13 2009-07-13
US61/270741 2009-07-13
PCT/US2010/041631 WO2011006147A1 (en) 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510784785.0A Division CN105476997B (zh) 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物

Publications (2)

Publication Number Publication Date
CN102639009A CN102639009A (zh) 2012-08-15
CN102639009B true CN102639009B (zh) 2016-01-20

Family

ID=43427658

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510784785.0A Active CN105476997B (zh) 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物
CN201080040828.XA Active CN102639009B (zh) 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510784785.0A Active CN105476997B (zh) 2009-07-10 2010-07-09 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物

Country Status (26)

Country Link
US (13) US8343974B2 (enExample)
EP (2) EP2451299B1 (enExample)
JP (6) JP5940448B2 (enExample)
KR (1) KR101850558B1 (enExample)
CN (2) CN105476997B (enExample)
AP (1) AP2012006124A0 (enExample)
AU (1) AU2010271178B2 (enExample)
BR (1) BR112012000614B1 (enExample)
CA (2) CA2804265C (enExample)
DK (1) DK2451299T3 (enExample)
EA (1) EA201270160A1 (enExample)
ES (1) ES2569238T3 (enExample)
HR (1) HRP20160406T1 (enExample)
HU (1) HUE027341T2 (enExample)
IL (3) IL304064A (enExample)
IN (1) IN2012DN01286A (enExample)
MX (2) MX2012000535A (enExample)
MY (2) MY189270A (enExample)
NZ (1) NZ598171A (enExample)
PH (2) PH12022552212A1 (enExample)
PL (1) PL2451299T3 (enExample)
SG (2) SG10201404000RA (enExample)
SI (1) SI2451299T1 (enExample)
SM (1) SMT201600110B (enExample)
WO (1) WO2011006147A1 (enExample)
ZA (2) ZA201201002B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201270160A1 (ru) * 2009-07-10 2012-07-30 Линзи О. Скотт Iii Способы и композиции для лечения медицинских состояний, связанных со щитовидной железой, с помощью восстановленных фолатов
WO2014143984A1 (en) * 2013-03-15 2014-09-18 Jarrow Formulas, Inc. Methods of producing nutritional supplements using mushrooms from the species poria cocos or flammulina velutipes
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
CN103705497B (zh) * 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
JP6424078B2 (ja) * 2014-02-13 2018-11-14 山洋電気株式会社 ステータ、ステータの製造方法、およびモータ
CN108992458A (zh) * 2018-06-12 2018-12-14 中国人民解放军第四军医大学 维生素b12用于制备预防和/或治疗术后认知功能障碍药物的应用
MX2022013140A (es) * 2020-04-22 2022-11-16 Iii Linzy O Scott Tratamiento de afecciones asociadas con la hormona tiroidea.
CN116887702A (zh) * 2020-07-27 2023-10-13 乔治·阿尤布 降低脑叶酸缺乏症的发病率或风险的方法
WO2022208216A1 (en) * 2021-03-31 2022-10-06 Boggarapu, Shravya An oral liquid formulation of metformin, teneligliptin, vitamin b12, atorvastatin and levothyroxine for diabetes

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
IT1229517B (it) 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
US6455288B1 (en) 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
US5681561A (en) 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6200950B1 (en) 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
DE60011877D1 (de) 1999-01-19 2004-08-05 Lidia M Vallarino Reaktionssystem und verfahren zur verstärkung der lumineszenz von makrocyclischen lanthanid(iii)-komplexen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000061154A1 (en) * 1999-04-08 2000-10-19 Khan Airudin S Composition, containing sublimed sulphur, for altering plasma homodyst(e) levels in humans
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020132753A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1372571A4 (en) 2001-03-20 2006-06-07 New Century Pharmaceuticals METHOD AND COMPOSITIONS FOR OPTIMIZING THE STABILITY OF BLOOD AND TISSUES CONFERRED BY CAMPTOTHECIN AND OTHER THERAPEUTIC COMPOUNDS BINDING ALBUMIN
US6506413B1 (en) 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
WO2003000010A2 (en) 2001-06-20 2003-01-03 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US20030195253A1 (en) 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
WO2003105561A2 (en) 2002-06-12 2003-12-24 Surromed, Inc. Method and devices for diagnosing and treating choroid plexus failure
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
AU2003301064A1 (en) 2002-12-17 2004-07-14 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004092334A2 (en) * 2003-04-09 2004-10-28 Jarrow Formulas, Inc. Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates
US7517342B2 (en) 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
US20050031544A1 (en) 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
ES2314485T3 (es) 2003-12-24 2009-03-16 N.V. Nutricia Composiciones que comprenden acido pantotenico o derivados del mismo y su uso para estimular el apetito.
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US20100087546A1 (en) 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
EP1912641B1 (en) 2005-06-21 2019-07-24 South Alabama Medical Science Foundation Methods and compositions containing natural folates for protecting against radiation damage
RU2005128993A (ru) 2005-09-08 2007-03-20 Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний
CA2867194C (en) 2005-10-07 2016-10-04 The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
WO2007070983A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CN101952546A (zh) 2007-12-17 2011-01-19 卢克斯创新有限公司 用于监测流经流体输导和容纳系统的流动的组合物和方法
EA201270160A1 (ru) * 2009-07-10 2012-07-30 Линзи О. Скотт Iii Способы и композиции для лечения медицинских состояний, связанных со щитовидной железой, с помощью восстановленных фолатов

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
原发性甲状腺功能减退血浆tHcy及血清叶酸、维生素B_(12)、胆固醇的变化;郗光霞等;《山西临床医药》;20010825(第08期);569-570 *
妇女增补叶酸预防神经管畸形成果推广的成本―效果分析;陈新!100083等;《中华医学科研管理杂志》;20010620(第02期);90-92 *
甲状腺功能亢进患者服用甲巯咪唑引起全血细胞减少1例;石青武;《临床荟萃》;20040205(第02期);108 *
老年甲减合并冠心病33例诊疗分析;黄绍军;《中外医疗》;20080411(第11期);21 *
营养性贫血;周晋;《中国实用内科杂志》;20090701(第7期);588-592 *

Also Published As

Publication number Publication date
US20160158237A1 (en) 2016-06-09
AU2010271178B2 (en) 2015-10-22
IL304064A (en) 2023-08-01
EP2451299A1 (en) 2012-05-16
US20130089623A1 (en) 2013-04-11
DK2451299T3 (en) 2016-05-30
JP2012532891A (ja) 2012-12-20
US20110008464A1 (en) 2011-01-13
US8575171B2 (en) 2013-11-05
IN2012DN01286A (enExample) 2015-05-15
MX350564B (es) 2017-09-11
US20220354853A1 (en) 2022-11-10
PH12019500495A1 (en) 2020-06-15
IL256966A (en) 2018-03-29
US9248130B2 (en) 2016-02-02
US20180185373A1 (en) 2018-07-05
SG10201404000RA (en) 2014-10-30
BR112012000614A8 (pt) 2018-06-12
NZ598171A (en) 2014-11-28
IL256966B2 (en) 2023-12-01
CA3031481A1 (en) 2011-02-13
WO2011006147A1 (en) 2011-01-13
IL256966B1 (en) 2023-08-01
JP2017186383A (ja) 2017-10-12
US8343974B2 (en) 2013-01-01
CA2804265A1 (en) 2011-02-13
CN105476997A (zh) 2016-04-13
US20190060318A1 (en) 2019-02-28
MY189270A (en) 2022-01-31
US20230201204A1 (en) 2023-06-29
BR112012000614B1 (pt) 2022-05-24
US20210000836A1 (en) 2021-01-07
PL2451299T3 (pl) 2016-09-30
US20170319589A1 (en) 2017-11-09
AU2010271178A1 (en) 2012-03-08
CA3031481C (en) 2021-03-16
IL217401A0 (en) 2012-02-29
KR101850558B1 (ko) 2018-04-19
MY181956A (en) 2021-01-15
CN102639009A (zh) 2012-08-15
SI2451299T1 (sl) 2016-10-28
EP2451299A4 (en) 2012-12-19
US20140030359A1 (en) 2014-01-30
ZA201301167B (en) 2014-12-23
EP2451299B1 (en) 2016-04-06
KR20120045010A (ko) 2012-05-08
BR112012000614A2 (pt) 2015-09-15
HRP20160406T1 (hr) 2016-05-20
EA201270160A1 (ru) 2012-07-30
JP2019089858A (ja) 2019-06-13
PH12022552212A1 (en) 2024-05-27
US20200163969A1 (en) 2020-05-28
AP2012006124A0 (en) 2012-02-29
JP2021091739A (ja) 2021-06-17
SG177613A1 (en) 2012-03-29
EP3053583B1 (en) 2020-10-14
JP5940448B2 (ja) 2016-06-29
US20190307756A1 (en) 2019-10-10
ES2569238T3 (es) 2016-05-09
HK1174798A1 (zh) 2013-06-21
MX2012000535A (es) 2012-03-29
HUE027341T2 (en) 2016-09-28
JP2023068107A (ja) 2023-05-16
US20210252002A1 (en) 2021-08-19
CA2804265C (en) 2019-02-19
JP2016047840A (ja) 2016-04-07
EP3053583A1 (en) 2016-08-10
CN105476997B (zh) 2019-06-21
ZA201201002B (en) 2013-05-29
SMT201600110B (it) 2016-07-01

Similar Documents

Publication Publication Date Title
CN102639009B (zh) 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物
AU2017204233B2 (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
HK1174798B (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
EA042030B1 (ru) Композиция для лечения дефицита фолатов в спинномозговой жидкости

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174798

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1174798

Country of ref document: HK